Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Min, Kyung-Jin | - |
dc.contributor.author | So, Kyeong A. | - |
dc.contributor.author | Lee, Jieun | - |
dc.contributor.author | Hong, Hye-Ri | - |
dc.contributor.author | Hong, Jin-Hwa | - |
dc.contributor.author | Lee, Jae-Kwan | - |
dc.contributor.author | Kim, Ae-Ree | - |
dc.date.accessioned | 2021-09-06T23:21:22Z | - |
dc.date.available | 2021-09-06T23:21:22Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012-01 | - |
dc.identifier.issn | 2005-0380 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/109148 | - |
dc.description.abstract | Objective: To validate the efficacy of Seeplex HPV4A ACE for the detection of high-risk (HR) human papillomavirus (HPV) and HPV 16 and/or HPV 18 genotypes as compared to the PCR method and the Cervista HPV assays in cervical swab samples. Methods: Besides liquid-based cytology, additional 97 cervical swab samples were collected for HPV genotyping by HPV4A ACE, Cervista HPV assays, and PCR method. To check the statistical differences, we also conducted the paired proportion test, Cohen' s kappa statistic, and a receiver operating characteristic curve. Results: Seeplex HPV4A ACE and the Cervista HPV HR showed substantial agreement with PCR for detection of HR HPVs (88.3%, kappa=0.767 and 81.7%, kappa=0.636, respectively). Seeplex HPV4A ACE also showed substantial agreement with the Cervista HPV 16/18 test (89.5%, kappa=0.628). Additionally, the sensitivity and specificity of Seeplex HPV4A ACE and Cervista HPV HR were 91.4% vs. 84.5% and 73.4%, vs. 72.7%, respectively, when those higher than low-grade squamous intraepithelial lesions were regarded as abnormalities. HPV genotyping for HPV 16/18 detected cervical intraepithelial neoplasias (CINs) better than HR HPV tests (66.7% vs. 24.6% by HPV4A ACE, 52.6% vs. 25.9% by Cervista HPV assays in CIN II or more, relatively). Conclusion: Seeplex HPV4A ACE is an effective method as the PCR and the Cervista HPV assays for the detection of HR HPVs and for genotyping of HPV 16 and 18. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOC GYNECOLOGY ONCOLOGY & COLPOSCOPY | - |
dc.subject | HUMAN-PAPILLOMAVIRUS INFECTIONS | - |
dc.subject | CERVICAL-CANCER | - |
dc.subject | RISK | - |
dc.subject | WOMEN | - |
dc.subject | PCR | - |
dc.subject | HR | - |
dc.subject | PERFORMANCE | - |
dc.subject | NEOPLASIA | - |
dc.subject | CYTOLOGY | - |
dc.title | Comparison of the Seeplex HPV4A ACE and the Cervista HPV assays for the detection of HPV in hybrid capture 2 positive media | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Min, Kyung-Jin | - |
dc.contributor.affiliatedAuthor | Hong, Jin-Hwa | - |
dc.contributor.affiliatedAuthor | Lee, Jae-Kwan | - |
dc.contributor.affiliatedAuthor | Kim, Ae-Ree | - |
dc.identifier.doi | 10.3802/jgo.2012.23.1.5 | - |
dc.identifier.scopusid | 2-s2.0-84863263730 | - |
dc.identifier.wosid | 000299027900002 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GYNECOLOGIC ONCOLOGY, v.23, no.1, pp.5 - 10 | - |
dc.relation.isPartOf | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.citation.title | JOURNAL OF GYNECOLOGIC ONCOLOGY | - |
dc.citation.volume | 23 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 5 | - |
dc.citation.endPage | 10 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001627047 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Obstetrics & Gynecology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Obstetrics & Gynecology | - |
dc.subject.keywordPlus | HUMAN-PAPILLOMAVIRUS INFECTIONS | - |
dc.subject.keywordPlus | CERVICAL-CANCER | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | WOMEN | - |
dc.subject.keywordPlus | PCR | - |
dc.subject.keywordPlus | HR | - |
dc.subject.keywordPlus | PERFORMANCE | - |
dc.subject.keywordPlus | NEOPLASIA | - |
dc.subject.keywordPlus | CYTOLOGY | - |
dc.subject.keywordAuthor | Cervista HPV HR | - |
dc.subject.keywordAuthor | Cervista HPV 16/18 | - |
dc.subject.keywordAuthor | High-risk HPV | - |
dc.subject.keywordAuthor | HPV 16 | - |
dc.subject.keywordAuthor | HPV 18 | - |
dc.subject.keywordAuthor | Seeplex HPV4A ACE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.